Clinicoecon Outcomes Res. 2012;4:337-47. doi: 10.2147/CEOR.S35487. Epub 2012 Nov 09.

The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model.

ClinicoEconomics and outcomes research : CEOR

Andrew van Herick, C Andy Schuetz, Peter Alperin, Michael F Bullano, Sanjeev Balu, Sanjay Gandhi

PMID: 23180970 PMCID: PMC3497874 DOI: 10.2147/CEOR.S35487

Abstract

PURPOSE: Many patients treated for dyslipidemia do not achieve recommended cholesterol goals despite the widespread availability of effective statins. Pharmaceutical claims show a strong tendency for patients to remain on their initially assigned treatment. With computer simulations, the impact of initial statin treatment decisions on medium- and long-term cardiovascular outcomes were examined.

PATIENTS AND METHODS: Using the Archimedes Model, three treatment scenarios were simulated. Patients initiated treatment with simvastatin (20, 40, or 80 mg), atorvastatin (10, 20, 40, or 80 mg), or rosuvastatin (10, 20, or 40 mg), and periodically intensified treatment. The simulated population consisted of 50,025 patients, aged 45-70 years, with low-density lipoprotein cholesterol exceeding goal. The proportion of patients initiating each dose was calibrated to United States pharmacy claims. Patients not reaching goal intensified the dose of their current statin or switched to an appropriate dose of rosuvastatin at rates matching pharmacy claims. Biomarkers and major adverse cardiovascular events (MACE) were tracked for 10 years and several high-risk subpopulations were analyzed. Statin models used biomarker effects from the STELLAR (Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin) trial and outcomes data from various trials.

RESULTS: Initiating therapy with rosuvastatin reduced MACE more than simvastatin or atorvastatin. The 5- year relative risk of MACE was 0.906 (95% confidence interval: 0.888-0.923; P < 0.001) for initial treatment with atorvastatin rather than simvastatin, 0.831 (0.812-0.850; P < 0.001) for rosuvastatin rather than simvastatin, and 0.918 (0.898-0.938; P < 0.001) for rosuvastatin rather than atorvastatin. Subgroups with higher MACE incidence experienced greater absolute benefit.

CONCLUSION: Considering observed rates of treatment intensification, initial treatment choices appear to significantly impact medium- and long-term cardiovascular risk. Patients at high cardiovascular risk are good candidates for aggressive initial therapy.

Keywords: atorvastatin; modeling; rosuvastatin; simulation; simvastatin

References

1. Am J Cardiol. 2003 Jul 15;92(2):152-60 - PubMed
2. Circulation. 2004 Jul 13;110(2):227-39 - PubMed
3. N Engl J Med. 2008 Nov 20;359(21):2195-207 - PubMed
4. N Engl J Med. 2005 Apr 7;352(14):1425-35 - PubMed
5. N Engl J Med. 1996 Oct 3;335(14):1001-9 - PubMed
6. JAMA. 2005 Nov 16;294(19):2437-45 - PubMed
7. Lancet. 2005 Oct 8;366(9493):1267-78 - PubMed
8. Curr Med Res Opin. 2010 Jan;26(1):121-8 - PubMed
9. Circulation. 2009 Jul 7;120(1):28-34 - PubMed
10. J Med Econ. 2012;15(6):1118-29 - PubMed
11. Lancet. 2003 Apr 5;361(9364):1149-58 - PubMed
12. JAMA. 2001 May 16;285(19):2486-97 - PubMed
13. Diabetes Care. 2008 Jan;31(1):173-5 - PubMed
14. Lancet. 2004 Aug 21-27;364(9435):685-96 - PubMed
15. Diabetes Care. 2003 Nov;26(11):3093-101 - PubMed
16. N Engl J Med. 2004 Apr 8;350(15):1495-504 - PubMed
17. BMJ. 1999 Dec 4;319(7223):1492-5 - PubMed
18. J Biomed Inform. 2002 Feb;35(1):37-50 - PubMed
19. Diabetes Care. 2003 Nov;26(11):3102-10 - PubMed
20. Lancet. 1994 Nov 19;344(8934):1383-9 - PubMed
21. Lancet. 2002 Jul 6;360(9326):7-22 - PubMed
22. Cleve Clin J Med. 2005 Sep;72(9):811-6 - PubMed

Publication Types

• Journal Article